What we do Vanta Bioscience Ltd is a preclinical contract research organization specializing in toxicology and safety assessment services for pharmaceutical, agrochemical, cosmetic, and chemical industries globally. |
Founded in 2,016 |
Market share Established as a center of excellence in GLP toxicology, serving clients in India and worldwide, with a specialized niche in preclinical safety assessments. |
Problem solved Provides risk assessment for safety evaluation of APIs, excipients, impurities, and conducts in vitro and in vivo toxicology studies helping clients meet regulatory safety requirements. |
Top clients or who we serve Serves pharmaceutical, medical devices, nutraceuticals, agrochemical, biotech, cosmetics, and chemical sectors; operates primarily B2B globally. |
Key management - |
Our journey and innovations Incorporated in 2016, converted to public company in 2017; acquired CRO facility in Chennai; expanded with subsidiaries focused on clinical research and R&D. |
Where we operate Headquartered in India with domestic and export operations, serving global clients in pharmaceutical and chemical sectors. |
Top products or what we offer Preclinical toxicology studies, risk assessment services, health-based exposure limits determination, and preclinical proof-of-concept studies in animal models. |
Top brands - |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Revenues are largely project-based and cyclical based on client contracts and preclinical study demand. |
Our industry position A niche player in GLP preclinical toxicology with growing reputation but recent financial losses affect current standing. |
Financial highlights Standalone FY25 revenue Rs 11.27 million with net loss Rs 26.59 million; consolidated revenue Rs 20.74 million with loss Rs 47.75 million. |
Geographical revenue split Domestic revenue contributes approximately 25% and exports about 75%. |
Order book - |
Whats driving growth Growing demand for regulatory compliant preclinical safety evaluations, global pharmaceutical development, and expansion of service offerings. |
Our future plans Focus on business revival, expanding clinical research services through subsidiaries, strategic investments, and addressing liquidity constraints. |
Our green promise - |
Our people and values Committed to corporate governance and compliance; workforce experienced but impacted by CIRP-related attrition. |
Key challenges ahead Liquidity issues, net losses, regulatory compliance lapses, and rebuilding trust post-CIRP proceedings. |
Interesting facts Converted from private to public company within a year, rapid acquisition of preclinical CRO, and listed on SME platform of BSE. |
Risks and strategy Facing financial and operational risks; management pursuing revival strategies, compliance improvements, and strategic capital infusion. |
